Review
Published · Updated · 1 min read
Pembrolizumab in laryngeal and pharyngeal tumors: partial and complete regression in two clinical cases
What it means for practice
Consider the potential role of immunotherapy in multidisciplinary treatment planning for laryngeal and pharyngeal tumors. The authors emphasize assessing PD-L1 expression using CPS for patient selection.
Summary
The article examines immunotherapy, particularly pembrolizumab, for malignant tumors of the larynx and pharynx. The authors discuss the limitations of traditional approaches—surgery, radiotherapy, and chemotherapy—in recurrent or metastatic disease and emphasize the need for new systemic treatment approaches.
The abstract cites KEYNOTE-048 and CheckMate-141 as evidence of benefits with pembrolizumab and nivolumab. It highlights the importance of assessing PD-L1 expression using the Combined Positive Score (CPS) for patient selection.
Two clinical cases treated with pembrolizumab are presented: one showed partial tumor regression and the other complete regression. Both had satisfactory tolerability without significant complications. The authors emphasize the potential of PD-1/PD-L1 inhibitors within multidisciplinary treatment strategies for these tumors.
The abstract does not provide quantitative results from the cited trials, CPS thresholds, dosing, treatment duration, or follow-up duration for the patients described. Specific limitations of the article are not stated either.
Source
-
Терапевтичний підхід при пухлинах гортані та глотки: від традиційних методів до імунотерапії.
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer